1-17 of 17
Nizar M. Tannir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma

James Brugarolas, Gregory Obara, Kathryn E. Beckermann, Brian Rini, Elaine T. Lam, James Hamilton, Thomas Schluep, Min Yi, So Wong, Zhongping Lily Mao, Erick Gamelin, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (11): 2402–2411.
https://doi.org/10.1158/1078-0432.CCR-23-3029
Published: 03 June 2024
View article titled, A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma
Open the PDF for A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma

Xian-De Liu, Yan-Ting Zhang, Daniel J. McGrail, Xuesong Zhang, Truong Lam, Anh Hoang, Elshad Hasanov, Ganiraju Manyam, Christine B. Peterson, Haifeng Zhu, Shwetha V. Kumar, Rehan Akbani, Patrick G. Pilie, Nizar M. Tannir, Guang Peng, Eric Jonasch
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 4002–4015.
https://doi.org/10.1158/1078-0432.CCR-23-1003
Published: 02 October 2023
View article titled, SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma
Open the PDF for SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C. Fan, Benjamin A. Gartrell, Oscar B. Goodman, Jr, Petros G. Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3248–3255.
https://doi.org/10.1158/1078-0432.CCR-22-0061
Published: 02 August 2022
View article titled, Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Open the PDF for Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial in another window
Includes: Supplementary data
Journal Articles

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Funda Meric-Bernstam, Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan, Angela DeMichele, Naomi B. Haas, Manish R. Patel, James J. Harding, Martin H. Voss, Taofeek K. Owonikoko, Bradley Carthon, Ramaprasad Srinivasan, Johanna C. Bendell, Yonchu Jenkins, Sam H. Whiting, Keith Orford, Mark K. Bennett, Todd M. Bauer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1540–1548.
https://doi.org/10.1158/1078-0432.CCR-21-2972
Published: 14 April 2022
View article titled, Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Open the PDF for Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial in another window
Includes: Supplementary data
Journal Articles

From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit

Toni K. Choueiri, Laurence Albiges, Michael B. Atkins, Ziad Bakouny, Gennady Bratslavsky, David A. Braun, Naomi B. Haas, John B.A.G. Haanen, A. Ari Hakimi, Michael A.S. Jewett, Eric Jonasch, William G. Kaelin, Jr, Payal Kapur, Chris Labaki, Bryan Lewis, David F. McDermott, Sumanta K. Pal, Kevin Pels, Susan Poteat, Thomas Powles, W. Kimryn Rathmell, Brian I. Rini, Sabina Signoretti, Nizar M. Tannir, Robert G. Uzzo, Hans J. Hammers
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 831–839.
https://doi.org/10.1158/1078-0432.CCR-21-3238
Published: 03 March 2022
View article titled, From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
Open the PDF for From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit in another window
Journal Articles

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

Meredith M. Regan, Opeyemi A. Jegede, Charlene M. Mantia, Thomas Powles, Lillian Werner, Robert J. Motzer, Nizar M. Tannir, Chung-Han Lee, Yoshihiko Tomita, Martin H. Voss, Elizabeth R. Plimack, Toni K. Choueiri, Brian I. Rini, Hans J. Hammers, Bernard Escudier, Laurence Albiges, Stephen Huo, Viviana Del Tejo, Brian Stwalley, Michael B. Atkins, David F. McDermott
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6687–6695.
https://doi.org/10.1158/1078-0432.CCR-21-2283
Published: 15 December 2021
View article titled, Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial
Open the PDF for Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

James J. Harding, Melinda Telli, Pamela Munster, Martin H. Voss, Jeffrey R. Infante, Angela DeMichele, Mark Dunphy, Mai H. Le, Chris Molineaux, Keith Orford, Frank Parlati, Sam H. Whiting, Mark K. Bennett, Nizar M. Tannir, Funda Meric-Bernstam
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (18): 4994–5003.
https://doi.org/10.1158/1078-0432.CCR-21-1204
Published: 15 September 2021
View article titled, A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
Open the PDF for A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma

Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, David F. McDermott, Robert J. Motzer, Abdallah Flaifel, Jean-Christophe Pignon, Miriam Ficial, Osvaldo Arén Frontera, Saby George, Thomas Powles, Frede Donskov, Michael R. Harrison, Philippe Barthélémy, Scott S. Tykodi, Judit Kocsis, Alain Ravaud, Jeronimo R. Rodriguez-Cid, Sumanta K. Pal, Andre M. Murad, Yuko Ishii, Shruti Shally Saggi, M. Brent McHenry, Brian I. Rini
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 78–86.
https://doi.org/10.1158/1078-0432.CCR-20-2063
Published: 04 January 2021
View article titled, Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Open the PDF for Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma

Robert A. Figlin, Nizar M. Tannir, Robert G. Uzzo, Scott S. Tykodi, David Y.T. Chen, Viraj Master, Anil Kapoor, Daniel Vaena, William Lowrance, Gennady Bratslavsky, Mark DeBenedette, Alicia Gamble, Ana Plachco, Marcus S. Norris, Joe Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, Christopher G. Wood
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2327–2336.
https://doi.org/10.1158/1078-0432.CCR-19-2427
Published: 15 May 2020
View article titled, Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma

Pavlos Msaouel, Nizar M. Tannir, Cheryl Lyn Walker
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (9): 2044–2049.
https://doi.org/10.1158/1078-0432.CCR-17-3296
Published: 30 April 2018
View article titled, A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma
Open the PDF for A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma in another window
Journal Articles

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas

Gabriel G. Malouf, Xiaoping Su, Jianping Zhang, Chad J. Creighton, Thai H. Ho, Yue Lu, Noël J.-M. Raynal, Jose A. Karam, Pheroze Tamboli, Frederick Allanick, Roger Mouawad, Jean-Philippe Spano, David Khayat, Christopher G. Wood, Jaroslav Jelinek, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6236–6246.
https://doi.org/10.1158/1078-0432.CCR-15-1217
Published: 15 December 2016
View article titled, DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas
Open the PDF for DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas in another window
Includes: Supplementary data
Journal Articles

Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case–Control Study

Julia Mendoza- Pérez, Jian Gu, Luis A. Herrera, Nizar M. Tannir, Surena F. Matin, Jose A. Karam, Maosheng Huang, David W. Chang, Christopher G. Wood, Xifeng Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (8): 2074–2082.
https://doi.org/10.1158/1078-0432.CCR-15-0977
Published: 14 April 2016
View article titled, Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case–Control Study
Open the PDF for Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case–Control Study in another window
Includes: Supplementary data
Journal Articles

Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes

Gabriel G. Malouf, Xiaoping Su, Hui Yao, Jianjun Gao, Liangwen Xiong, Qiuming He, Eva Compérat, Jérôme Couturier, Vincent Molinié, Bernard Escudier, Philippe Camparo, Denaha J. Doss, Erika J. Thompson, David Khayat, Christopher G. Wood, Willie Yu, Bin T. Teh, John Weinstein, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (15): 4129–4140.
https://doi.org/10.1158/1078-0432.CCR-13-3036
Published: 31 July 2014
View article titled, Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes
Open the PDF for Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes in another window
Includes: Supplementary data
Journal Articles

Genomic Heterogeneity of Translocation Renal Cell Carcinoma

Gabriel G. Malouf, Federico A. Monzon, Jérôme Couturier, Vincent Molinié, Bernard Escudier, Philippe Camparo, Xiaoping Su, Hui Yao, Pheroze Tamboli, Dolores Lopez-Terrada, Maria Picken, Marileila Garcia, Asha S. Multani, Sen Pathak, Christopher G. Wood, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4673–4684.
https://doi.org/10.1158/1078-0432.CCR-12-3825
Published: 02 September 2013
View article titled, Genomic Heterogeneity of Translocation Renal Cell Carcinoma
Open the PDF for Genomic Heterogeneity of Translocation Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Ana M. Aparicio, Andrea L. Harzstark, Paul G. Corn, Sijin Wen, John C. Araujo, Shi-Ming Tu, Lance C. Pagliaro, Jeri Kim, Randall E. Millikan, Charles Ryan, Nizar M. Tannir, Amado J. Zurita, Paul Mathew, Wadih Arap, Patricia Troncoso, Peter F. Thall, Christopher J. Logothetis
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (13): 3621–3630.
https://doi.org/10.1158/1078-0432.CCR-12-3791
Published: 30 June 2013
View article titled, Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer
Open the PDF for Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

David S. Hong, Said M. Sebti, Robert A. Newman, Michelle A. Blaskovich, Lei Ye, Robert F. Gagel, Stacy Moulder, Jennifer J. Wheler, Aung Naing, Nizar M. Tannir, Chaan S. Ng, Steven I. Sherman, Adel K. El Naggar, Rabia Khan, Jon Trent, John J. Wright, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (22): 7061–7068.
https://doi.org/10.1158/1078-0432.CCR-09-1241
Published: 11 November 2009
View article titled, Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies
Open the PDF for Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies in another window
Journal Articles

Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases

Paul Mathew, Peter F. Thall, Corazon D. Bucana, William K. Oh, Michael J. Morris, Donnah M. Jones, Marcella M. Johnson, Sijin Wen, Lance C. Pagliaro, Nizar M. Tannir, Shi-Ming Tu, Anthony A. Meluch, Lon Smith, Lorenzo Cohen, Sun-Jin Kim, Patricia Troncoso, Isaiah J. Fidler, Christopher J. Logothetis
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5816–5824.
https://doi.org/10.1158/1078-0432.CCR-07-1269
Published: 01 October 2007
View article titled, Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases
Open the PDF for Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases in another window